meRfi®-GM
NCT02335411 - KEYNOTE-059 - >/= 3rd line - Pembrolizumab vs Cisplatin + Fluorouracil (5-FU) + Pembrolizumab vs Capecitabine + Pembrolizumab & Gastric cancer / Gastric adenocarcinoma / Stomach cancer / Gastroesophageal junction adenocarcinoma (GEJ)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
This is a study of pembrolizumab (MK-3475) for advanced Gastric cancer / Gastric adenocarcinoma / Stomach cancer or Gastroesophageal junction adenocarcinoma (GEJ); pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-naïve; pembrolizumab will also be evaluated as combination therapy with cisplatin and 5-Fluorouracil (5-FU) or (Japan only) capecitabine in treatment-naïve participants. The primary study hypothesis is that pembrolizumab will provide a clinically meaningful Overall Response Rate (ORR).
Primary outcome measures:
Safety, Objective Response Rate (ORR)
Pembrolizumab showed promising efficacy in a clinical trial of patients with previously treated, advanced stomach or gastroesophageal junction …